Pharmacopeia

CWP-0237

Salbutamol

Obstetric & Reproductive · Level 3 Respiratory · Level 2

Core pharmacology

Chemical Pharmaceutics

Synthetic sympathomimetic amine

racemic mixture of the R- and S-isomers. The R-isomer has 150 times greater affinity for the beta2-receptor than the S-isomer and the S-isomer has been associated with toxicity

Presentation

- Clear colourless solution containing 50-500mcg/ml after dilution for IV infusion
- Metered dose inhaler (100mcg) and dry powder (200-400mcg) for inhalation
- Clear colourless solution containing 2.5-5mg/ml for nebulization
- Oral preparation (syrup or tablets)

Mechanism of action

β2 agonist - GsPCR: Adenylate cyclase activated, cAMP

On cell membranes: ↑Na+/K+ ATPase activity and hyperpolarisation

Mild β1 agonist effects

Physiological effects

CVS:
- At high doses, especially IV, B1 effects cause increased inotropy and chronotropy
- At lower doses, B2 effects predominate and may cause a decreased SVR due to skeletal muscle vasodilation
- May precipitate arrhythmias, particularly in the presence of hypokalaemia
Resp:
- Bronchodilation, leading to increased FEV1
- Interferes with hypoxic pulmonary vasoconstriction and may precipitate shunt leading to hypoxia
Metabolic/Other:
- Na/K/ATPase is stimulated and transports K into cells leading to hypokalaemia
- Increased blood glucose
- Beta adrenergic activity leads to increased production of lactate
- Tremor
Uterus:
- Relaxes gravid uterus
- 10% crosses the placenta and causes fetal tachycardia

Protein binding

Only weak protein binding

Volume of distribution

Vd (IV) 4-5L/kg

Metabolism

Converted by liver to inactive metabolite (esterified / oxidative deamination / conjugation with glucuronide)

Excretion

Excreted urine as 40% free dug and 60% metabolite
Small amount in faeces

Half-life

T1/2 5hrs

Special Points

Appears to potentiate NDMR

Route And Dose

Inh/Neb/IV

Class Group

Short-acting beta-2 adrenergic agonist bronchodilator with uterine-relaxant effects.

Main Action

Beta-2 adrenoceptor agonism increases intracellular cAMP, producing bronchial smooth-muscle relaxation and uterine relaxation.

Adverse Effects Toxicity

Adverse effects include tremor, palpitations or tachycardia, anxiety or insomnia, hypokalaemia, hyperglycaemia and lactic acidosis. Nausea, vomiting and postural hypotension may also occur.

Introduction

short-acting, selective beta2-adrenergic receptor agonist used in the treatment of asthma and COPD.

Indications Uses

(i) the symptomatic relief and prevention of bronchospasm due to bronchial asthma, chronic bronchitis, reversible obstructive airway disease, and other chronic bronchopulmonary disorders in which bronchospasm is a complicating factor, and/or (ii) the acute prophylaxis against exercise-induced bronchospasm and other stimuli known to induce bronchospasm

Absorption

After inhalation, about 10% of the dose reaches the bronchial tree. The remainder is swallowed and undergoes gastrointestinal absorption and first-pass metabolism.